Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Do not inject from a wrongly diluted vial
Confirm expiration dates on both the peptide and the BAC water
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
This preparation is designed solely for parenteral use only after addition of solutions that require dilution or must be dissolved in an aqueous vehicle prior
US$ 23.51
US$ 28.80
US$ 29.94
US$ 24.54
US$ 29.13
US$ 29.25
